Answers are grounded in this paper and cite their sources.
The threat of emerging viral diseases presents a critical societal need for broad-spectrum antiviral therapeutics. A key contribution to antiviral options would be a broad-spectrum agent that can treat a wide variety of viral diseases. Vacuolar H-ATPase (V-ATPase), a host proton pump critical for endosomal acidification, serves an essential role in facilitating the entry of multiple viruses. Diphyllin, a naturally occurring V-ATPase inhibitor, displays potent antiviral activity but is limited by suboptimal drug-like properties, including selectivity and metabolic instability. Molecular modeling enabled the identification of a conserved binding site on the V-ATPase a-subunit consisting of three distinct sub-pockets. Docking analyses of ninety-five known diphyllin derivatives demonstrated that active analogs effectively occupy all three subpockets, informing a structure-based design approach. A library of novel diphyllin analogs with modifications to a single-ring system showed 50-fold increases in potency for antiviral activity against Ebola, Venezuelan equine encephalitis, and Chikungunya viruses and exhibiting improvements in metabolic stability and permeability.
No takes yet. Share an insight, caveat, or question.
Elkabbany et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: